As indicated in Figure 2a, β2AR agonist treatment was more closely associated with the reduction in PD risk compared with non-β2AR-agonist treatment (RR = 0.859, 95% CI, 0.741 to 0.995. Here, ADRB2 is linked to Parkinson disease.